The Weekly Mind Reader: Psych Drugs Can Treat COVID

by Staff Writer
March 24, 2023 at 11:15 AM UTC

minor ear anomalies are more common in people with depressive order.

Psychotropic drugs consistently arise from a broader scope of practice, so it is not surprising that many are repurposed for non-psychiatric indications. This week, The Journal of Clinical Psychiatry published a narrative review taking a look at fluvoxamine, a little known OCD drug, to see if it can effectively treat COVID.

Researchers have long suspected that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), possesses anti-inflammatory properties. In one University of Washington trial reviewed in the narrative, patients who were given the drug within seven days of developing COVID symptoms were less likely to experience clinical deterioration or require hospitalization compared to patients who were given a placebo. The medication didn’t reduce symptoms, but the researchers concluded that it may have prevented severe illness.

The JCP narrative goes on to detail a list of drugs that show promise in treating other chronic conditions including long COVID, Alzheimer’s disease and cancer. 

The available results are encouraging, but plenty of drugs have fizzled out after showing early potential, the narrative authors said, adding, “…promising candidate drugs must be tested in RCTs to gain sufficient evidence for widespread adoption, including regulators’ approving these drugs for new uses.” 

You can read the full study here. 

 

MORE PSYCHIATRY AND CNS NEWS THIS WEEK

  • The ENLIGHTEN-Early Study evaluated the weight gain effects of combination olanzapine and samidorphan (OLZ/SAM) versus olanzapine in early-phase schizophrenia and bipolar I disorder. The results could help avoid expanding patients’ waistlines more than necessary. This JCP paper is free to access.
  • If you have ever been unsure about which aspects of an acute psychosis evaluation are the most likely to yield meaningful information, the case report outlined in the latest edition of Rounds in the General Hospital should prove useful.
  • A recent The Primary Care Companion for CNS Disorders analysis took a hard look at the economic burden faced by adults with ADHD. Patients who don’t take medication had more doctor visits and hospital stays than those taking medication. They also spent at least twice as much money on their healthcare.
  • You may be happy about the impending end of the COVID emergency that was declared more than three years ago. But some changes to federal regulations are pending that could make it harder to practice psychiatry.
  • Looking ahead to next week, a case study follows a man with late-onset OCD who experienced recurrent religious obsessions. What’s going on here?
  • And finally, in our “Tweet of the Week,” the cast of the wildly popular TV show Ted Lasso visited the White House to raise awareness for the importance of mental health.

 

NEW AT CME INSTITUTE
Click to earn free accredited CME credit.

A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder

Intranasal ketamine induced rapid antidepressant effects versus placebo but did not significantly change suicidal ideation scores in patients with alcohol use disorder and suicidal ideation with past attempt.

Gregory H. Jones and others

Case Report

Inhalant Screening in Early Adolescence: Missed Opportunity to Prevent Escalation to Polysubstance Use and Related Consequences

The authors present a case of polysubstance use in an adolescent for whom undetected inhalant use played a key role in escalation of substance use and psychiatric comorbidities.

Jennifer Yokoyama and others